ATE397665T1 - Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon - Google Patents

Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Info

Publication number: ATE397665T1
Authority: AT; Austria
Prior art keywords: beta; lymphotoxin; complexes; cell; alpha
Prior art date: 1992-12-04

Application number

AT94907045T

Other languages

English (en)

Inventor

Jeffrey Browning

Carl F Ware

Original Assignee

Biogen Idec Inc

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-04

Filing date

1993-12-02

Publication date

2008-06-15

1993-12-02 Application filed by Biogen Idec Inc, Univ California filed Critical Biogen Idec Inc

2008-06-15 Application granted granted Critical

2008-06-15 Publication of ATE397665T1 publication Critical patent/ATE397665T1/de

Links

102000003959 Lymphotoxin-beta Human genes 0.000 title abstract 5
108090000362 Lymphotoxin-beta Proteins 0.000 title abstract 5
239000000825 pharmaceutical preparation Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 6
210000004027 cell Anatomy 0.000 abstract 4
108090000623 proteins and genes Proteins 0.000 abstract 4
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 3
102000004169 proteins and genes Human genes 0.000 abstract 3
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 2
230000001105 regulatory effect Effects 0.000 abstract 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
210000004408 hybridoma Anatomy 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
239000002644 phorbol ester Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT94907045T 1992-12-04 1993-12-02 Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon ATE397665T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US99030492A	1992-12-04	1992-12-04

Publications (1)

Publication Number	Publication Date
ATE397665T1 true ATE397665T1 (de)	2008-06-15

Family

ID=25536005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94907045T ATE397665T1 (de)	1992-12-04	1993-12-02	Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Country Status (7)

Country	Link
EP (1)	EP0672143B1 (de)
JP (3)	JPH08507201A (de)
AT (1)	ATE397665T1 (de)
AU (1)	AU692146B2 (de)
CA (1)	CA2150249A1 (de)
DE (1)	DE69334224D1 (de)
WO (1)	WO1994013808A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0809510T3 (da) *	1995-01-26	2004-10-04	Biogen Inc	Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler
US6312691B1 (en)	1996-01-26	2001-11-06	Jeffrey L. Browning	Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US7078493B1 (en)	1995-03-15	2006-07-18	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like genes
US8110659B1 (en)	1995-03-15	2012-02-07	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US7094564B1 (en)	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en)	1995-06-05	2008-09-23	Human Genome Sciences, Inc.	Polynucleotides encoding human tumor necrosis factor receptor-like2
AU6166396A (en) *	1995-06-07	1996-12-30	Biogen, Inc.	Complexes of modified lymphotoxins as pharmaceutical prepara tions
US5925351A (en)	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO1997033904A1 (en) *	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
US6713061B1 (en)	1996-03-12	2004-03-30	Human Genome Sciences, Inc.	Death domain containing receptors
US7357927B2 (en)	1996-03-12	2008-04-15	Human Genome Sciences, Inc.	Death domain containing receptors
US7255854B1 (en)	1996-10-25	2007-08-14	Biogen, Inc.	Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
SI0954333T1 (sl) *	1996-10-25	2006-12-31	Biogen Idec Inc	Topni limfotoksin-beta receptorji, anti-limfotoksin receptorska protitelesa in anti-limfotoksin ligandna protitelesa kot terapevtska sredstva za zdravljenje imunoloskih bolezni
NZ335353A (en) *	1996-10-25	2000-09-29	Biogen Inc	Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
US6998108B1 (en) *	1997-07-07	2006-02-14	La Jolla Institute For Allergy And Immunology	Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en)	1998-01-30	2006-06-13	Biogen Idec Ma, Inc.	Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en)	1998-10-09	2000-04-20	Biogen, Inc.	Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
EE200300179A (et)	2000-10-13	2003-08-15	Biogen, Inc.	Humaniseeritud LT-ß-R-i vastased antikehad
CA2491480A1 (en)	2002-07-01	2004-01-08	Biogen, Inc.	Humanized anti-lymphotoxin beta receptor antibodies
WO2004058191A2 (en) *	2002-12-20	2004-07-15	Biogen Idec Ma Inc.	Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US20050163782A1 (en)	2003-06-27	2005-07-28	Biogen Idec Ma Inc.	Modified binding molecules comprising connecting peptides
SG151294A1 (en)	2004-03-23	2009-04-30	Biogen Idec Inc	Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
WO2006114284A2 (en) *	2005-04-25	2006-11-02	Pluta Rechtsanwalts Gmbh	AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY
US8338376B2 (en)	2006-10-20	2012-12-25	Biogen Idec Ma Inc.	Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja)	2006-10-20	2010-03-04	バイオジェン・アイデック・エムエイ・インコーポレイテッド	可溶性リンホトキシンβレセプターによる脱髄障害の処置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE201879T1 (de) *	1990-06-27	2001-06-15	Biogen Inc	Oberflächenkomplexbildung von lymphotoxin

1993
- 1993-12-02 EP EP94907045A patent/EP0672143B1/de not_active Expired - Lifetime
- 1993-12-02 AU AU60483/94A patent/AU692146B2/en not_active Ceased
- 1993-12-02 DE DE69334224T patent/DE69334224D1/de not_active Expired - Fee Related
- 1993-12-02 WO PCT/US1993/011669 patent/WO1994013808A2/en not_active Ceased
- 1993-12-02 CA CA002150249A patent/CA2150249A1/en not_active Abandoned
- 1993-12-02 JP JP6514235A patent/JPH08507201A/ja not_active Withdrawn
- 1993-12-02 AT AT94907045T patent/ATE397665T1/de not_active IP Right Cessation
2003
- 2003-11-12 JP JP2003383099A patent/JP2004135676A/ja not_active Withdrawn
2006
- 2006-09-19 JP JP2006253541A patent/JP2007039464A/ja active Pending

Also Published As

Publication number	Publication date
AU692146B2 (en)	1998-06-04
DE69334224D1 (de)	2008-07-17
JP2007039464A (ja)	2007-02-15
JP2004135676A (ja)	2004-05-13
EP0672143B1 (de)	2008-06-04
CA2150249A1 (en)	1994-06-23
WO1994013808A3 (en)	1994-08-04
WO1994013808A2 (en)	1994-06-23
AU6048394A (en)	1994-07-04
JPH08507201A (ja)	1996-08-06
HK1013835A1 (en)	1999-09-10
EP0672143A1 (de)	1995-09-20

Legal Events

Date	Code	Title	Description
2008-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69334224D1 (de)	2008-07-17	Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
DK0536299T3 (da)	2001-07-09	Overfladekompleksbundet lymfotolksin
Shin et al.	1998	In vivo expression of transforming growth factor-β1 in humans: stimulation by cyclosporine: 1
Dinarello	1998	Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzyme a
Zhang et al.	1988	Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6.
Goldstein	2007	History of the discovery of the thymosins
BG60256B1 (bg)	1994-03-24	Рекомбинантен метод за получаване на лимфотоксин
KR900700592A (ko)	1990-08-16	용해성 티-4 유도체
EP0107498A2 (de)	1984-05-02	Synergistische Humaninterferonaktivität
Sanderson	1988	Interleukin-5: an eosinophil growth and activation factor
Schneider et al.	1985	The role of arginase in the immune response
SE9002589L (sv)	1990-08-07	Neutrofil-aktiverande peptid-2
Takane et al.	2000	Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice
Shearer et al.	1987	Regulation of cell growth by interferon
Barbanti-Brodano et al.	1973	Selective killing of macrophages by amanitin-albumin conjugates
ATE70453T1 (de)	1992-01-15	Verwendung von interleukin-1-proteinen gegen arthritis.
KR900005994A (ko)	1990-05-07	혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
Persico	2024	Low molecular weight inhibitors of interleukin-1
Sehgal et al.	1982	Interferon and its inducers
Tovey et al.	1979	The use of the chemostat to study the relationship between cell growth rate, viability, and the effect of interferon on L 1210 cells
Ortaldo et al.	1982	Augmentation of human natural killer cells with human leukocyte and human recombinant leukocyte interferon
ATE292173T1 (de)	2005-04-15	Lipidspaltender enzymkomplex
Borecký	1986	Current view on the perspectives of interferon therapy
Griffiths et al.	1988	Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia
Higgins et al.	2020	Interleukin-1 inhibitors and their significance in rheumatoid arthritis